Membranous Nephropathy: Rituximab, the Ponticelli Regimen, or a Titer-Guided Sequence
A single patient, newly biopsied with membranous nephropathy and a high anti-PLA2R titer. The disagreement isn't whether to treat — it's whether a real trial result favoring the harsher regimen should change the reflexive first choice.
Daniel R. teaches high school shop and still runs the after-school robotics club two evenings a week, which is how he first noticed his boots weren't lacing the way they used to — a detail he mentioned to his primary care physician almost as an aside before the visit turned into something else. Six weeks of ankle swelling and foamy, hard-to-flush urine led to a nephrology referral, a 24-hour collection at 6.4 grams of protein, and a biopsy: membranous nephropathy, stage II-III on electron microscopy, with subepithelial deposits consistent with the diagnosis he'd never heard of before this month. His hypertension has been quietly controlled on lisinopril for over a decade; there is no diabetes, no prior kidney disease, nothing in his history that anticipated this.
His anti-PLA2R titer came back at 182 RU/mL — high enough that it changes the conversation, not just confirms the diagnosis. A low or moderate titer carries a real chance of spontaneous remission within a year, the kind of number that argues for watchful waiting or a gentler first-line drug. A titer this high does the opposite: it predicts a lower probability of remission without treatment and, more specifically, a lower probability of durable remission from the milder regimens, which is exactly the population STARMEN's own randomized comparison was built to inform. STARMEN pitted tacrolimus-plus-rituximab against a modified Ponticelli regimen — alternating corticosteroids and cyclophosphamide — head to head, and its real result runs against the instinct to reach for the gentler-looking option by default: the cyclophosphamide-based arm achieved a higher rate of complete remission at 24 months, not merely a comparable one. That finding sits uncomfortably next to rituximab's own genuinely strong record, from MENTOR's noninferiority-with-more-durability result against cyclosporine, and it's the actual reason his case isn't a simple one.
In clinic, after the biopsy result
Rituximab first. MENTOR randomized this exact drug against cyclosporine and found it noninferior at twelve months and more durable at twenty-four — fewer relapses, not just comparable remission. He's fifty-eight with a normal life expectancy ahead of him; cyclophosphamide's cumulative gonadal, bladder, and malignancy risk is a real cost we'd be choosing to accept before we've even given the gentler option a fair trial.
If his titer were moderate rather than high, I wouldn't be having a debate at all — rituximab would simply be the answer.
I take the toxicity argument seriously, and I'm not proposing cyclophosphamide reflexively — but STARMEN tested this exact question, tacrolimus-rituximab against a modified Ponticelli regimen, head to head, and the cyclophosphamide arm won on complete remission at twenty-four months. That's not a tie we're breaking on toxicity preference; it's a real result running against the gentler-first instinct.
Citing MENTOR against cyclosporine doesn't answer STARMEN's finding against rituximab specifically — those are two different comparisons, and the one that actually matches what we're deciding here favored the harsher regimen.
You're both reading real data correctly, and neither trial actually settles this alone. KDIGO's 2021 framework treats anti-PLA2R titer as something to reassess over time, not a single fork in the road. Start rituximab — it's still the better first move for most patients his titer doesn't automatically disqualify — but set the checkpoint now, explicitly: titer and twenty-four-hour protein at six months, with a pre-agreed threshold for escalating to the Ponticelli regimen if the serologic response is inadequate.
That isn't splitting the difference for its own sake. It means we don't commit him to cyclophosphamide's toxicity before we know rituximab hasn't worked, and we don't let a high titer talk us into abandoning a genuinely effective, gentler option out of anticipatory pessimism.
Agreed: rituximab now, two doses, with anti-PLA2R titer and 24-hour urine protein rechecked at six months against an explicit written threshold — a titer that hasn't fallen substantially, or proteinuria still in the nephrotic range, triggers a direct conversation about the Ponticelli regimen rather than a repeat course of rituximab.
Continue rituximab monitoring alone; no further immunosuppression escalation.
Move directly to the modified Ponticelli regimen — not a second rituximab course.